elranatamab
pfizer
['magnetismm-3', 'mmsm', 'elranatamab']
#eha2023 | presents follow up data from the phase 2 magnetismm-3 trial of elranatamab in rrmm. 61% orr, mrd neg 89.7%. 70.7% experienced grade 3/4 teaes, most commonly hematologic. #mmsm #myeloma 
The Multiple Myeloma (MM) Hub is an online educational resource run in collaboration with the European School of Haematology @ESHaematology #mmsm #myeloma